Drug Type CAR-NK |
Synonyms Anti-EGFR chimeric antigen receptor NK cell therapy - CytoImmune Therapeutics + [2] |
Target |
Mechanism EGFR modulators(Epidermal growth factor receptor erbB1 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization Cytovia Therapeutics, Inc.Startup |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Discovery | US | Cytovia Therapeutics, Inc.Startup | 03 Aug 2020 |